-
2023 - 09 - 20
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation - 20/09/2023
-
2023 - 07 - 21
Le Groupe Menarini reçoit un avis positif du CHMP recommandant l'approbation CE - 21/07/2023
-
2023 - 07 - 07
Fair Play Menarini International Awards, les champions du Fair Play ont séduit l
-
2023 - 07 - 02
Fair Play Menarini International Award
-
2023 - 06 - 19
Fair Play Menarini International Award Announces the Winners of the XXVII
-
2023 - 05 - 24
Menarini présente à Florence sa dernière monographie artistique
-
2023 - 04 - 13
XXVII Edition du Prix International Fair Play Menarini
-
2023 - 01 - 30
Press Release MENARINI Group - Stemline
-
2022 - 08 - 23
Press Release Menarini Group's Elacestrant
-
2022 - 08 - 12
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patient
-
2022 - 07 - 27
Karyopharm and Menarini Group Receive Full Marketing Authorization
-
2022 - 06 - 07
Press Release"Menarini Group and Radius Health, Inc. present a subgroup analysis
-
2021 - 10 - 20
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results
-
2021 - 04 - 08
Lancement du projet des Menarini Pills of Art Junior
-
2020 - 11 - 16
Press Release by Menarini Corporate
-
2020 - 10 - 27
Menarini Group: Committed to Fighting Today's COVID-19 Pandemic
-
2020 - 07 - 24
Menarini Group and Radius Health Announce Global License Agreement for the Development
-
2020 - 06 - 10
Menarini Group Completes Acquisition of Stemline Therapeutics
-
2020 - 06 - 08
Menarini investit 150 millions d'euros pour une nouvelle usine en Italie
-
2022 - 06 - 07
Menarini Invests 150 Million Euros in a New Pharmaceutical Plant in Italy
-
2020 - 05 - 04
Menarini Press Release
